ADMA — ADMA Biologics Inc
Is ADMA overbought or oversold? Here is the current MarketMoodz read.
ADMA Biologics Inc (ADMA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $13.63. The rating moved from Overbought to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$13.63
- Last changeMoved from Overbought to Neutral on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
ADMA Biologics is a small‑cap plasma‑derived immunoglobulin specialist with a product mix that benefits from recurring demand but remains exposed to plasma supply, reimbursement and execution variability. Near‑term performance will hinge on manufacturing utilization, margin improvement, and steadiness of collections and distributor flows. Sector themes that favor specialty infusion channels are supportive, but company‑specific liquidity and competition from larger producers elevate downside risk. Monitor upcoming operational metrics (collection volumes, shipment cadence, gross margin) and any regulatory or label developments as the primary catalysts for clearer directional movement.
Key factors
- Niche plasma‑derived immunoglobulin product portfolio with recurring revenue characteristics tied to chronic indications
- Manufacturing and supply chain scale: revenue sensitive to plasma collection capacity, throughput and gross margin improvements from capacity utilization
- Reimbursement environment: stable coverage for immunoglobulin therapies but pricing pressure and payer scrutiny can affect unit economics
- Distributor and specialty channel trends that favor specialty infusion and biopharma services could support prescription flow and collection economics
- Financial position and cash flow: historically uneven profitability and periodic cash needs raise sensitivity to execution on cost control and working capital
- Regulatory and approval pathway clarity for new indications or label expansions could unlock upside if achieved
Risks
- Plasma supply shocks or collection disruptions that constrain product availability and revenue
- Intense competition from larger, integrated plasma and biologics companies with deeper discounting power and broader distribution
- Reimbursement pressure, increased payer audits or clawbacks that compress realized prices (broader healthcare regulatory tightening noted across Medicare/Medicaid)
- Execution risk on manufacturing scale‑up, quality control, or regulatory inspections that could delay shipments or approvals
- Balance sheet and liquidity risk — need for capital raises or dilution if cash burn continues or growth investments require funding
- Single‑product/indication concentration risk if a significant portion of revenue depends on a small number of therapies
- Market sentiment volatility for small‑cap biotech/biologics names, amplifying downside in risk‑off periods
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ADMA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.